Evidence map›Paper›PMID 30488762›Full record

ArticleCell cycle (Georgetown, Tex.)2018

CircPCNXL2 sponges miR-153 to promote the proliferation and invasion of renal cancer cells through upregulating ZEB2.

Bisheng Zhou, Pengyi Zheng, Zhijun Li, Huibing Li, Xiaohui Wang, Zhenguo Shi, Qingjiang Han

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Circular RNAs in kidney disease and cancer.Nature reviews. Nephrology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bisheng Zhoua Department of Urology Surgery , The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology , Luoyang , China.
Pengyi Zhenga Department of Urology Surgery , The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology , Luoyang , China.
Zhijun Lia Department of Urology Surgery , The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology , Luoyang , China.ORCID 0000-0001-8835-6877
Huibing Lia Department of Urology Surgery , The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology , Luoyang , China.
Xiaohui Wanga Department of Urology Surgery , The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology , Luoyang , China.
Zhenguo Shia Department of Urology Surgery , The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology , Luoyang , China.
Qingjiang Hana Department of Urology Surgery , The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology , Luoyang , China.
First Affiliated Hospital of Henan University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence showed that circular RNAs (circRNAs) play critical roles in tumorigenesis. However, the roles and underlying mechanisms of circRNAs in clear cell renal cell carcinoma (ccRCC) remain unclear. In the present study, we identified a novel circRNA circPCNXL2, which was significantly upregulated in ccRCC by circular RNA microarray. Further analysis revealed that circPCNXL2 was significantly increased and correlated with poor overall survival of ccRCC patients. Function assays revealed that circPCNXL2 knockdown reduced RCC cells proliferation, invasion in vitro, and decreased tumor growth in vivo. In mechanism study, we showed that circPCNXL2 could be bind to miR-153 as a miRNA sponge to regulate ZEB2 expression in RCC progression. In addition, our data reported that the effects of circPCNXL2 inhibition on RCC cells proliferation and invasion could be abolished by miR-153 inhibitors. Altogether, we demonstrated that circPCNXL2 could regulate RCC cells proliferation and invasion by miR-153/ZEB2 axis, suggesting circPCNXL2 might serve as a potential therapeutic target for ccRCC treatment.

Indexed as

AnimalsAntagomirsCarcinoma, Renal CellCell Line, TumorCell MovementCell ProliferationG1 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMiceMice, NudeMicroRNAsRNARNA, CircularRNA InterferenceAntagomirsMicroRNAsMIRN153 microRNA, humanRNARNA, CircularRNA, Small InterferingZEB2 protein, humanZinc Finger E-box Binding Homeobox 2circPCNXL2circRNAClear cell renal cell carcinomamiR-153ZEB2

Identifiers

PMID30488762
PMCPMC6300113
OpenAlexW2902705829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.